|
Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
Apr 2023 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
|
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases |
Apr 2023 |
Internal and Emergency Medicine |
Myelodysplastic Syndromes (MDS) |
|
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
Apr 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
PNH and complement gene variants |
Apr 2023 |
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
Apr 2023 |
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
|
Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia |
Apr 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study |
Apr 2023 |
Journal of Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
|
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome |
Apr 2023 |
Blood Cancer |
Myelodysplastic Syndromes (MDS) |
|
Raising the bar for lower-risk myelodysplastic syndromes |
Apr 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
